Patients & Caregivers
Study Administers IMG-7289 to First Patients with Myelofibrosis
The first patients have been dosed in a Phase 1/2 clinical trial of IMG-7289 for the treatment of myelofibrosis (MF), according to Imago BioSciences.
Sancilio Gets Rare Pediatric Disease Designation for Sickle Cell Disease Treatment
Sancilio Pharmaceuticals announced that the FDA has granted Rare Pediatric Disease designation to Altemia Soft Gelatin Capsules for sickle cell disease in children.
Executive Director of TargetCancer Talks Cholangiocarcinoma
Jim Palma sits down with
to discuss cholangiocarcinoma, the disease with which Paul Poth, his brother-in-law and the founder of TargetCancer, was diagnosed.
Somatuline Depot Injection Receives Expanded Approval for Carcinoid Syndrome
Almost 3 years since its approval to treat patients with neuroendocrine tumors, Somatuline Depot has received a supplemental indication to treat carcinoid syndrome.
Aliqopa Gets FDA Approval to Treat Follicular Lymphoma
Accelerated Approval was granted to Bayer Healthcare Pharmaceuticals’ Aliqopa (copanlisib) today for the treatment of follicular lymphoma.
FDA Approves Biosimilar for Cancer Treatment
Amgen’s Mvasi (bevacizumab-awwb), a biosimilar to Avastin, is now FDA-approved for use in adults to treat multiple types of cancer.
New Research Collaboration Aims to Accelerate AML Therapy Research
Daiichi Sankyo and MD Anderson Cancer Center announced a multi-year collaboration dedicated to accelerating the development of novel therapies to treat AML.
New Data Reveals Potential Target for Neuroblastoma Treatment
A study led by oncologists at the Children’s Hospital of Philadelphia discovered a new target that could lead to the treatment and prevention of neuroblastoma.
New Combination Shows Promising Results in Clear Renal Cell Carcinoma
Clinical data reveals that X4P-001-IO with Inlyta demonstrated encouraging disease control rates and durable responses in clear cell renal cell carcinoma.
Yervoy or Opdivo: Which is Better for Advanced Melanoma?
Two clinical trials published in NEJM show Opdivo (nivolumab) to be the superior drug.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.